1. Home
  2. MD vs BEAM Comparison

MD vs BEAM Comparison

Compare MD & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pediatrix Medical Group Inc.

MD

Pediatrix Medical Group Inc.

N/A

Current Price

$25.91

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$24.75

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MD
BEAM
Founded
1979
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.6B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
MD
BEAM
Price
$25.91
$24.75
Analyst Decision
Hold
Buy
Analyst Count
4
12
Target Price
$20.50
$50.75
AVG Volume (30 Days)
638.9K
1.8M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
263.03
82.31
EPS
0.85
N/A
Revenue
$1,913,849,000.00
$24,000.00
Revenue This Year
$3.72
N/A
Revenue Next Year
$2.62
$33.77
P/E Ratio
$31.21
N/A
Revenue Growth
N/A
33.33
52 Week Low
$15.70
$20.23
52 Week High
$28.86
$38.26

Technical Indicators

Market Signals
Indicator
MD
BEAM
Relative Strength Index (RSI) 48.83 32.83
Support Level $25.24 $21.63
Resistance Level $27.23 $28.87
Average True Range (ATR) 0.79 1.25
MACD -0.04 -0.63
Stochastic Oscillator 53.81 6.66

Price Performance

Historical Comparison
MD
BEAM

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: